NHRI Enters Technology Transfer Agreement of DBPR186 with Taivex Therapeutics Corp.

National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Jiayi) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights of the small molecule Mertansine conjugate, DBPR186, with global patents.

About DBPR186
Phospholipid phosphatidylserine (PS), abundant on the external surfaces of cancer cells, is an established target molecule for cancer therapy. DBPR186 is a developmental drug candidate for delivering therapeutic agent, DM-1, that associates with PS.

About Taivex
Taivex Therapeutics Corp., founded in 2010, focuses on the development of novel, niche, and targeted anti-cancer drugs. For more information, please visit http://www.taivex.com/en/index.html

About IBPR of the NHRI
Institute of Biotechnology and Pharmaceutical Research of the NHRI is a mission-driven drug discovery and development engine with vertical and horizontal coordination and integration. For more information, visit https://ibpr.nhri.org.tw/en/

Share Button

Comments are closed.